Uses of immunoconjugates targeting CD138

US10117932B2 · kind B2 · utility

Assignees

• Biotest AG · DE
• IMMUNOGEN, INC. · US

Inventors

• Gregor Schulz · Umkirch, DE
• Frank Osterroth · Dietzenbach, DE
• Thomas Haeder · Dreieich, DE
• Christoph Bruecher · Eschborn, DE
• Gabriele Niemann · Walzbachtal, DE
• André Engling · Frankfurt, DE
• Christoph Uherek · Seligenstadt, DE
• Benjamin Daelken · Frankfurt am Main, DE
• Andrea Wartenberg-Demand · Linden, DE
• Chantal Zuber · Frankfurt am Main, DE
• Marcus Gutscher · Langen, DE
• Katrin Bernoester · Wiesbaden, DE
• Martin Koenig · Wiesbaden, DE

Key dates

• Filing date: Dec 7, 2012
• Grant date: Nov 6, 2018
• Expiry date: Oct 21, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.